Lab Sector Vs. CMS Battle Heats Up As Medicare Agency Moves Forward With 2018 Rates
Test-makers and labs say the agency is missing large swaths of the market in making its "market-based" lab payment calculation, but CMS stands by its data, and finalized 2018 lab fee schedule rates. Could next steps be in Congress, or the courts?
You may also be interested in...
Coverage Decisions For AlloMap Molecular Testing To Detect Cardiac Allograft Rejections Left Up To MACs
The US CMS has proposed that due to low Medicare use, it will not nationally cover AlloMap molecular tests to detect cardiac allograft rejections.
A lawsuit challenging the US Centers for Medicare and Medicaid Services implementation laboratory test payment reforms was dismissed by a US District Court for lack of subject matter jurisdiction. The case was filed by the American Clinical Laboratory Association and joined by AdvaMedDx and laboratory companies.
The US Medicare agency has proposed several changes to the status quo in its planned 2019 Medicare physician fee schedule and clinical laboratory fee schedule that will impact reimbursements for telehealth services, the advanced imaging industry and clinical laboratories.